pyrazines has been researched along with Kidney Neoplasms in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 19 (45.24) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Li, J; Ruan, N; Wu, G; Xia, Q; Xu, Y; Zhang, Q | 1 |
| Albiges, L; Cancel, M; Choueiri, TK; Frigault, MM; Heng, DYC; L'Hernault, A; Lee, JL; Mellemgaard, A; Ottesen, LH; Signoretti, S; Szijgyarto, Z; Verheijen, RB | 1 |
| Massari, F; Mollica, V; Rizzo, A | 1 |
| Chen, XF; Chen, Z; Gu, DH; Sun, X; Zheng, B; Zhu, H; Zhu, WL | 1 |
| Adeniran, A; Alva, A; Balzer-Haas, N; Bjarnason, GA; Cole, S; George, DJ; Heng, DYC; Humphrey, P; Lara, PN; Narayan, V; Pal, SK; Plets, M; Shuch, B; Stein, M; Tangen, C; Thompson, IM; Tretiakova, M; Vaishampayan, U; Wright, J; Zhang, T | 1 |
| Markham, A | 1 |
| Albiges, L; Arkenau, HT; Choueiri, TK; Clark, EA; Frigault, MM; Gardner, H; Handzel, AA; Heng, DYC; Jonasch, E; Morgan, S; Pal, SK; Plimack, E; Powles, T | 1 |
| Gilbert, JA | 1 |
| Fenner, A | 1 |
| Agarwal, N; Hahn, AW; Shuch, B | 1 |
| Gong, YD; Hwang, KY; Kang, JH; Kim, KH; Kim, N; Kim, SG; Kim, SY; Lee, JS; Lee, SH; Lee, WK; Park, JB | 1 |
| Camidge, DR; Ching, KA; Christensen, JG; Clark, JW; Diamond, JR; Eckhardt, SG; Kanteti, R; Lira, ME; LoRusso, PM; Salgia, R; Schoenmakers, EF; Varella-Garcia, M; Wilner, K; Xu, LG | 1 |
| Adams, GP; Balachandran, S; Chen, P; Nogusa, S; Peri, S; Shaller, C; Simmons, H; Thapa, RJ | 1 |
| Balachandran, S; Chen, P; Cheung, M; Nogusa, S; Pei, J; Peri, S; Testa, JR; Thapa, RJ | 1 |
| Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
| Asano, T; Isono, M; Ito, K; Sato, A | 1 |
| Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ | 1 |
| Gong, YD; Hong, D; Kang, JH; Kim, N; Kim, SY; Lee, JS; Lee, SH; Lee, WK; Sung, TW | 1 |
| Kang, JH; Kim, SY; Lee, SH | 1 |
| Jia, H; Kong, F; Liu, J; Liu, L; Liu, X; Luan, Y; Sun, C; Wang, J; Xue, X | 1 |
| Bouchard, P; Brown, L; Carson, WE; Chaudhury, AR; Go, MR; Guenterberg, K; Guttridge, DC; Hade, E; Ladner, KJ; Lesinski, GB; Lewis, A; Quimper, M; Raig, ET; Shah, NN; Young, G | 1 |
| Berg, M; Childs, R; Lundqvist, A; Smith, A; Yokoyama, H | 1 |
| Brauer, KM; Bringmann, A; Brossart, P; Held, SA; Schaub, A; von Schwarzenberg, K | 1 |
| Bukowski, RM; Burk, R; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Hill, J; Rybicki, LR; Vaziri, SA | 1 |
| Brooks, AD; Jacobsen, KM; Li, W; Sayers, TJ; Shanker, A | 1 |
| Chen, G; Lin, Z; Liu, S; Xiang, Y; Zhu, L | 1 |
| Giubellino, A; Linehan, WM; Neckers, L; Sourbier, C; Sudarshan, S; Valera-Romero, V; Yang, Y | 1 |
| Asano, T; Ito, K; Sato, A; Sumitomo, M | 1 |
| Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R | 1 |
| Arima, N; Kawada, H | 1 |
| Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE | 1 |
| An, J; Fisher, M; Rettig, MB; Sun, Y | 1 |
| Hatake, K; Mishima, Y; Terui, Y | 1 |
| Bacik, J; Drucker, B; Kondagunta, GV; Marion, S; Mazumdar, M; Motzer, RJ; Russo, P; Schwartz, L | 1 |
| An, J; Fisher, M; Rettig, MB | 1 |
| Alexandre, J | 1 |
| Jaehde, U; Scheulen, ME; Simons, S | 1 |
| Kondagunta, GV; Motzer, RJ; Ronnen, EA | 1 |
| An, J; Rettig, MB | 1 |
| Arsos, G; de Haas, M; de Klerk, J; de Vrey, E; Weijs, L | 1 |
| Brooks, AD; Elliott, PJ; Murphy, WJ; Sayers, TJ; Shanker, A; Smyth, MJ; Takeda, K; Tristan, CA; Wine, JW; Yagita, H | 1 |
| Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE | 1 |
4 review(s) available for pyrazines and Kidney Neoplasms
| Article | Year |
|---|---|
Savolitinib: First Approval.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; China; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Approval; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pyrazines; Stomach Neoplasms; Triazines | 2021 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
[Proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Bortezomib].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
7 trial(s) available for pyrazines and Kidney Neoplasms
| Article | Year |
|---|---|
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Single-Blind Method; Sunitinib; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Topics: Aged; Anilides; Canada; Carcinoma, Renal Cell; Crizotinib; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridines; Sunitinib; Triazines; United States | 2021 |
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-met; Pyrazines; Triazines; Young Adult | 2017 |
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2004 |
Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome | 2004 |
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pyrazines; Survival Rate | 1998 |
31 other study(ies) available for pyrazines and Kidney Neoplasms
| Article | Year |
|---|---|
Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma.
Topics: Acyltransferases; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Membrane Proteins; Neoplasm Proteins; Pyrazines; Pyridines; Wnt Signaling Pathway | 2020 |
Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamao
Topics: Carcinoma, Renal Cell; Goals; Humans; Kidney Neoplasms; Pyrazines; Sunitinib; Triazines | 2020 |
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth.
Topics: Animals; Carcinoma, Renal Cell; Cell Proliferation; DNA-Activated Protein Kinase; Female; Humans; Kidney Neoplasms; Mice; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2020 |
Savolitinib for MET-driven papillary renal cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Treatment Outcome; Triazines | 2017 |
Kidney cancer: Savolitinib - a saviour for papillary RCC?
Topics: Biomarkers; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrazines; Triazines | 2017 |
Current Treatment Landscape of Advanced Papillary Renal Cancer.
Topics: Biomarkers; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Pyrazines; Triazines | 2017 |
Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Topics: Allosteric Regulation; Carcinoma, Renal Cell; Cell Line, Tumor; GTP-Binding Proteins; HEK293 Cells; Humans; Kidney Neoplasms; Neoplasm Proteins; Protein Domains; Protein Glutamine gamma Glutamyltransferase 2; Pyrazines; Transglutaminases | 2018 |
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Heterozygote; Humans; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Methionine; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazines; Receptor Protein-Tyrosine Kinases; Sequence Analysis, DNA; Threonine; Treatment Failure; Triazoles | 2013 |
Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; CD27 Ligand; Cell Death; Cell Line, Tumor; Humans; Interferon-gamma; Kidney Neoplasms; Mice; Necrosis; Phosphorylation; Protein Binding; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases; Recombinant Fusion Proteins; Signal Transduction; Species Specificity; STAT1 Transcription Factor | 2013 |
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Enzyme Activation; Humans; I-kappa B Kinase; Interferon-gamma; Kidney Neoplasms; Necrosis; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinases | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Stress; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Kidney Neoplasms; Mice, Inbred BALB C; Panobinostat; Pyrazines; Ubiquitinated Proteins | 2014 |
Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Chloroquine; DNA Damage; Doxorubicin; Female; GTP-Binding Proteins; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Binding; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-mdm2; Pyrazines; RNA-Binding Proteins; Transglutaminases; Tumor Suppressor Protein p53 | 2016 |
Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Topics: Apoptosis; Carcinoma, Renal Cell; Enzyme Inhibitors; GTP-Binding Proteins; Humans; Kidney Neoplasms; Protein Binding; Protein Glutamine gamma Glutamyltransferase 2; Pyrazines; Transglutaminases; Tumor Suppressor Protein p53 | 2016 |
Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways.
Topics: Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Cell Survival; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured; Vasodilator Agents | 2016 |
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Caspase 8; Fas-Associated Death Domain Protein; Humans; Interferon-alpha; Kidney Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2008 |
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Topics: Adoptive Transfer; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Lewis Lung; Caspase 8; Cell Proliferation; Granzymes; Humans; Kidney Neoplasms; Killer Cells, Natural; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; T-Lymphocytes, Regulatory | 2009 |
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARgamma ligand troglitazone.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Chromans; Cytokines; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thiazolidinediones; Troglitazone | 2009 |
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cyclin-Dependent Kinase Inhibitor p21; DNA Methylation; Gene Expression Profiling; Humans; Inhibitor of Apoptosis Proteins; Kidney Neoplasms; Microtubule-Associated Proteins; Mutation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Survivin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Pyrazines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
Topics: Adult; Boronic Acids; Bortezomib; Creatinine; Desensitization, Immunologic; Graft Survival; Humans; Isoantibodies; Kidney Neoplasms; Living Donors; Lymphocytes; Male; Protease Inhibitors; Pyrazines; Treatment Outcome | 2009 |
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cisplatin; Humans; Kidney Neoplasms; Leiomyomatosis; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Reactive Oxygen Species; Transplantation, Heterologous | 2010 |
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Topics: Acetylation; Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Fluorine Radioisotopes; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; Mice; Pyrazines; Tumor Cells, Cultured; Ubiquitination; Vorinostat | 2012 |
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Immunohistochemistry; Kidney Diseases, Cystic; Kidney Neoplasms; Metformin; Mice; Pyrazines; Treatment Outcome; Tuberous Sclerosis | 2012 |
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Kidney Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2004 |
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; Cell Survival; Genes, Tumor Suppressor; Humans; Kidney Neoplasms; NF-kappa B; Paclitaxel; Pyrazines; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Medullary renal cell carcinoma and response to therapy with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Humans; Kidney Medulla; Kidney Neoplasms; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2006 |
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines | 2007 |
Intense [18F]FDG tongue uptake in a case of acipimox-related angio-oedema during FDG-PET myocardial viability study.
Topics: Administration, Oral; Angioedema; Fluorodeoxyglucose F18; Humans; Hypolipidemic Agents; Kidney Neoplasms; Myocardium; Perfusion; Positron-Emission Tomography; Pyrazines; Tongue | 2007 |
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunoblotting; Kidney Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitochondrial Membranes; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2008 |